Outcome of 12-weeks Triple Therapy (TT), including Sofosbuvir (SOF), Ribavirin and Pegylated interferon-Alfa in all non-cirrhotic patients with chronic Hepatitis-C Genotype-3 infection

Abstract

Objective: The treatment of hepatitis C virus (HCV) infection is rapidly evolving from interferon and ribavirin which is the standard of care (SOC) for genotype 3-infection, to the most effective Triple therapy by adding Sofosbuvir to the SOC regimen. We assessed the efficacy of Sofosbuvir based triple therapy in new and previously non-responder patients with Hepatitis-C Genotype-3 infection, the most common genotype infecting Pakistani community.

Study Design: Prospective / multi-center study

Place and Duration of Study: This study was conducted at the Pharmacology Department, Khyber Girls Medical College, Peshawar Pakistan from October 2015 to April 2016.

Materials and Methods: We recruited a total of 75 patients and were assigned into three groups (Group A, B, C). Group-A as treatment naive, group-B as non-responder to conventional interferon plus Ribavirin and group-C as non-responder to peg-interferon and ribavirin. Sofosbuvir based triple therapy was given for 12-weeks. The primary end point was Sustained Virological Response12 (SVR12), which is HCV-RNA level<40IU/ml at 12weeks after completion of therapy.

Results: Among75 patients, male-female ratio was n=51and n=24respectively.Each group has25-cases. Rate of SVR12 was 100%(n=25/25) in group-A, 92%(n=23/25) in group-B and 88%(=22/25) in group-C.

Conclusion: Our findings suggest that addition of sofosbuvir to the standard therapy results in the better achievement of SVR in new and previously non-responder cases with Chronic Hepatitis-C genotype-3 infections.